Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Edesa Biotech Inc (EDSA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/17/2025: EDSA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -38.74% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.76M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) 29576 | Beta 0.38 | 52 Weeks Range 1.55 - 5.59 | Updated Date 06/22/2025 |
52 Weeks Range 1.55 - 5.59 | Updated Date 06/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.55 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -35.29% | Return on Equity (TTM) -58.78% |
Valuation
Trailing PE - | Forward PE 0.17 | Enterprise Value 12852336 | Price to Sales(TTM) 120477.93 |
Enterprise Value 12852336 | Price to Sales(TTM) 120477.93 | ||
Enterprise Value to Revenue 128525.38 | Enterprise Value to EBITDA -1.25 | Shares Outstanding 7022680 | Shares Floating 3695684 |
Shares Outstanding 7022680 | Shares Floating 3695684 | ||
Percent Insiders 28.41 | Percent Institutions 43.53 |
Analyst Ratings
Rating 5 | Target Price 13 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Edesa Biotech Inc
Company Overview
History and Background
Edesa Biotech Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory and immune-related diseases. Founded to address unmet medical needs, it has evolved through various clinical trials and strategic partnerships.
Core Business Areas
- Dermatology: Development of treatments for dermatological conditions like atopic dermatitis (eczema).
- Inflammatory Diseases: Research and development of therapies for broader inflammatory conditions, including those affecting the gut.
Leadership and Structure
The company is led by a management team with expertise in drug development and clinical trials. Details of the organizational structure and specific team members can be found on their investor relations website.
Top Products and Market Share
Key Offerings
- EB01 (topical cream): A non-steroidal topical cream being developed for chronic allergic contact dermatitis (ACD). Market share is currently 0 as it is in clinical trials. Competitors in the topical steroid/non-steroidal treatment space include companies marketing products like Eucrisa (crisaborole) from Pfizer.
- EB05 (anti-TLR4 mAb): A monoclonal antibody being investigated for the treatment of acute respiratory distress syndrome (ARDS). Market share is currently 0 as it is in clinical trials. Competitors include companies focused on developing ARDS therapies, such as those targeting inflammatory pathways.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, with significant investment in drug development. The inflammatory and immune diseases market is large and growing.
Positioning
Edesa Biotech is a clinical-stage company seeking to carve a niche in the dermatology and inflammatory disease markets. Its competitive advantage lies in its novel therapeutic candidates and focused approach.
Total Addressable Market (TAM)
The global market for atopic dermatitis treatments and ARDS is significant and expected to grow. The TAM for atopic dermatitis is estimated to be in the billions of dollars annually. Edesa is positioned to capture a portion of this TAM through its clinical programs.
Upturn SWOT Analysis
Strengths
- Novel therapeutic candidates
- Focused therapeutic areas
- Potential for addressing unmet medical needs
Weaknesses
- Limited financial resources
- Early-stage clinical development
- High regulatory risk
Opportunities
- Successful clinical trial outcomes
- Strategic partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent expiry or challenges
Competitors and Market Share
Key Competitors
- PFE
- SNY
- BMY
Competitive Landscape
Edesa faces competition from larger, more established pharmaceutical companies with greater resources and broader product portfolios. However, Edesa's focused approach and novel therapies may provide a competitive advantage.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Limited historical revenue growth due to the company's development stage.
Future Projections: Future growth is dependent on successful clinical trials and potential regulatory approvals.
Recent Initiatives: Recent initiatives include advancing clinical trials for EB01 and EB05, and seeking strategic partnerships.
Summary
Edesa Biotech is a clinical-stage biopharmaceutical company with promising therapies in development. Its success hinges on positive clinical trial outcomes and securing partnerships to support its pipeline. The company faces inherent risks associated with drug development and competition from larger players but offers potential upside if its lead candidates prove successful.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Edesa Biotech Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The biopharmaceutical industry is subject to rapid change, and predictions may not be accurate. Market share estimates are based on general industry knowledge and may not reflect precise figures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Edesa Biotech Inc
Exchange NASDAQ | Headquaters Markham, ON, Canada | ||
IPO Launch date 2015-11-05 | CEO, Company Secretary & Director Dr. Pardeep Nijhawan FRCPC, M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 16 | Website https://www.edesabiotech.com |
Full time employees 16 | Website https://www.edesabiotech.com | ||
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.